|
시장보고서
상품코드
2075153
자가면역성 다선성 증후군 1형(APS-1) 시장 : 진단별, 치료별, 제형별, 투여 경로별, 발증 연령별, 유통 채널별, 지역별Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis, By Treatment, By Dosage Form, By Route of Administration, By Age of Onset, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
세계의 자가면역성 다선성 증후군 1형(APS-1) 시장은 2026년에 2억 9,920만 달러로 추정되고 있으며, 2033년까지 3억 8,070만 달러에 달할 것으로 전망되고 있습니다. 2026-2033년에는 CAGR 3.5%로 성장할 것으로 예측됩니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 2억 9,920만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 3.50% | 2033년 시장 규모 예측 : | 3억 8,070만 달러 |
자가면역성 다선 증후군 1형(APS-1)은 자가면역성 다내분비 질환·칸디다증·외배엽성 이영양증(APECED)으로도 알려져 있으며, 부신, 부갑상선, 생식선 등 여러 내분비선 및 기타 조직이 자가면역에 의해 파괴되어 발생하는 희귀한 다기관 질환입니다. APS1은 조직 특이적 유전자의 발현을 조절하고 중추성 면역 관용을 유도하는 AIRE 유전자(자가면역 조절 인자)의 변이에 의해 유발됩니다. AIRE 기능 상실은 면역 관용의 붕괴를 초래하며, 그 결과 여러 장기에 대한 자가면역 공격이 발생합니다. APS1의 일반적인 임상적 특징으로는 부갑상선 기능 저하증, 원발성 부신 기능 부전, 만성 점막·피부 칸디다증, 그리고 생식선 기능 부전이 포함됩니다. 발병 시기가 빠르고 여러 장기에 미치는 영향이 심각하므로 APS1 환자는 평생에 걸친 관리와 경과 관찰이 필요합니다.
시장 역학 :
전 세계 자가면역성 다선증후군 1형(APS-1) 유병률의 증가에 따라 전 세계 APS-1 시장은 유망한 성장 기회를 맞이할 것으로 전망됩니다. 고위험군 집단을 대상으로 한 유전자 선별 검사 프로그램이 조기 진단률 향상에 기여하고 있습니다. 또한 면역학적 질환의 기전을 규명하고 새로운 관용 유도 요법을 개발하기 위한 연구의 진전도 시장 성장을 촉진하고 있습니다. 그러나 승인된 표적 치료제의 부족과 치료 선택지의 제한이 여전히 시장의 발목을 잡고 있습니다. 한편, 희귀질환에 대한 인식을 높이기 위한 노력과 새로운 생물제제 개발에 주력하는 움직임은 매력적인 기회를 창출할 가능성을 내포하고 있습니다. 희귀질환인 APS-1은 연구개발을 촉진하기 위한 희귀질환 치료제 지정 및 인센티브의 혜택을 받을 가능성이 있습니다. 현재 진행 중인 연구는 근본적인 메커니즘에 대한 이해를 심화하고, 보다 표적화된 효과적인 치료법의 실현을 목표로 하고 있습니다. 그러나 환자 수가 제한적이기 때문에 대규모 임상시험이나 의약품 개발에는 여전히 과제가 남아 있습니다.
제약 기업, 연구 기관, 환자 지원 단체 간의 협력은 APS-1에 대한 연구를 추진하고, 이 복잡한 자가면역 증후군을 앓고 있는 분들의 삶의 질을 향상시키기 위해 필수적입니다. 시장 역학은 의료의 발전과 희귀질환 치료를 지원하는 규제 환경 모두의 영향을 받고 있습니다.
본 조사의 주요 특징 :
- 이 보고서는 전 세계 자가면역성 다선증후군 1형(APS-1) 시장에 대한 상세한 분석을 제공함과 동시에, 2025년을 기준 연도로 하여 2026-2033년의 예측 기간 중 시장 규모 및 연평균 성장률(CAGR)을 제시하고 있습니다.
- 또한 다양한 부문에서 잠재적인 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 보고서에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 자가면역성 다선증후군 1형(APS-1) 시장의 주요 업체들을 분석하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 자가면역성 다선증후군 1형(APS-1) 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 자가면역성 다선증후군 1형(APS-1) 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 자가면역성 다선성 증후군 1형(APS-1) 시장 : 진단별, 2021-2033년
제5장 세계의 자가면역성 다선성 증후군 1형(APS-1) 시장 : 치료별, 2021-2033년
제6장 세계의 자가면역성 다선성 증후군 1형(APS-1) 시장 : 제형별, 2021-2033년
제7장 세계의 자가면역성 다선성 증후군 1형(APS-1) 시장 : 투여 경로별, 2021-2033년
제8장 세계의 자가면역성 다선성 증후군 1형(APS-1) 시장 : 발증 연령별, 2021-2033년
제9장 세계의 자가면역성 다선성 증후군 1형(APS-1) 시장 : 유통 채널별, 2021-2033년
제10장 세계의 자가면역성 다선성 증후군 1형(APS-1) 시장 : 지역별, 2021-2033년
제11장 경쟁 구도
제12장 섹션
KSA 26.07.07Global Autoimmune Polyglandular Syndrome Type 1 Market is estimated to be valued at USD 299.2 Mn in 2026 and is expected to reach USD 380.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 299.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.50% | 2033 Value Projection: | USD 380.7 Mn |
Autoimmune polyglandular syndrome type 1 (APS1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare multisystem disorder caused by the autoimmune destruction of several endocrine glands like the adrenals, parathyroid glands, gonads, and other tissues. APS1 results from mutations in the AIRE gene (autoimmune regulator), which regulates the expression of tissue-specific genes and promotes central tolerance induction. Loss of function of AIRE leads to failures in immune tolerance, leading to autoimmune attacks on multiple organs. Common clinical features of APS1 include hypoparathyroidism, primary adrenal insufficiency, chronic mucocutaneous candidiasis, and gonadal failure. Early onset and severity of multiorgan involvement require lifelong management and monitoring of APS1 patients.
Market Dynamics:
The global autoimmune polyglandular syndrome type 1 market is projected to witness lucrative growth opportunities owing to rising APS1 disease prevalence worldwide. Genetic screening programs for high-risk ethnic populations are driving the early diagnosis rate. Increasing research into understanding immunological disease mechanisms and developing novel tolerance-inducing therapies is also fueling market growth. However, a lack of approved targeted drugs and limited treatment options continue to hamper the market. Meanwhile, initiatives to enhance rare disease awareness and focus on developing new biologics hold potential to create attractive opportunities. As a rare disease, APS-1 may benefit from orphan drug designations and incentives to encourage research and development. Ongoing research aims to deepen our understanding of the underlying mechanisms, allowing for more targeted and effective treatments. However, the limited patient population poses challenges for large-scale clinical trials and drug development.
Collaboration between pharmaceutical companies, research institutions, and patient advocacy groups is crucial for advancing APS-1 research and improving the quality of life for individuals affected by this complex autoimmune syndrome. The market dynamics are influenced by both medical advancements and the regulatory landscape supporting rare disease treatments.
Key features of the study:
- This report provides in-depth analysis of the global autoimmune polyglandular syndrome type 1 market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2026-2033, considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global autoimmune polyglandular syndrome type 1 market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global autoimmune polyglandular syndrome type 1 market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global autoimmune polyglandular syndrome type 1 market
Detailed Segmentation:
- By Diagnosis (Revenue, USD Mn, 2021 - 2033)
- Serum Autoimmune Screen
- End-organ Function Tests
- Blood Tests
- By Treatment (Revenue, USD Mn, 2021 - 2033)
- Medication
- Antifungal Agents
- Fluconazole
- Itraconazole
- Calcitriol
- Corticosteroids
- Others (Hormone Replacement Therapy, etc.)
- By Dosage Form (Revenue, USD Mn, 2021 - 2033)
- Tablet
- Capsule
- Others
- By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Oral
- Others
- By Age of Onset (Revenue, USD Mn, 2021 - 2033)
- Childhood
- Adult
- Adolescent
- By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players:
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- F.Hoffmann-La Roche Ltd.
- Zydus Cadila
- Lupin
- Amneal Pharmaceuticals LLC.
- Cipla Inc.
- Aurobindo Pharma
- Glenmark Pharmaceuticals Limited
- Eli Lilly and Company
- Sun Pharmaceutical Industries Ltd.
- Allergan
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical Company Limited
- Abbott
- LEO Pharma A/S
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis
- Global Autoimmune Polyglandular Syndrome Type 1 Market, By Treatment
- Global Autoimmune Polyglandular Syndrome Type 1 Market, By Dosage Form
- Global Autoimmune Polyglandular Syndrome Type 1 Market, By Route of Administration
- Global Autoimmune Polyglandular Syndrome Type 1 Market, By Age of Onset
- Global Autoimmune Polyglandular Syndrome Type 1 Market, By Distribution Channel
- Global Autoimmune Polyglandular Syndrome Type 1 Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increased incidence of autoimmune disorders
- Growing Genetic Research Insights
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Service offering Portfolio
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Pipeline Analysis
4. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Serum Autoimmune Screen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- End-organ Function Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Blood Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
5. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Treatment, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Medication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Antifungal Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Fluconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Itraconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Calcitriol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Others (Hormone Replacement Therapy, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
6. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Dosage Form, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Capsule
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
7. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Route of Administration, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
8. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Age of Onset, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Childhood
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Adolescent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
9. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
10. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022 -2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- North Africa
- Central Africa
- South Africa
11. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zydus Cadila
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amneal Pharmaceuticals LLC.
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Inc.
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aurobindo Pharma
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allergan
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Abbott
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- LEO Pharma A/S
- Company Highlights
- Product & Service Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
12. Section
- Research Methodology
- About us
